ADMA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ADMA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Good Sign:
Piotroski F-Score is 8, indicates a very healthy situation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
ADMA Biologics has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.
The historical rank and industry rank for ADMA Biologics's Piotroski F-Score or its related term are showing as below:
During the past 13 years, the highest Piotroski F-Score of ADMA Biologics was 8. The lowest was 1. And the median was 4.
The historical data trend for ADMA Biologics's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADMA Biologics Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Piotroski F-Score | Get a 7-Day Free Trial |
![]() |
![]() |
3.00 | 4.00 | 5.00 | 6.00 | - |
ADMA Biologics Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Piotroski F-Score | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
6.00 | 6.00 | 8.00 | 8.00 | - |
For the Biotechnology subindustry, ADMA Biologics's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, ADMA Biologics's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where ADMA Biologics's Piotroski F-Score falls into.
How is the Piotroski F-Score calculated?
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Sep24) TTM: | Last Year (Sep23) TTM: |
Net Income was -17.645 + 17.806 + 32.062 + 35.909 = $68.1 Mil. Cash Flow from Operations was 17.597 + -2.218 + 45.646 + 25.028 = $86.1 Mil. Revenue was 73.904 + 81.875 + 107.191 + 119.839 = $382.8 Mil. Gross Profit was 31.086 + 39.108 + 57.453 + 59.659 = $187.3 Mil. Average Total Assets from the begining of this year (Sep23) to the end of this year (Sep24) was (348.997 + 329.182 + 350.875 + 376.399 + 390.618) / 5 = $359.2142 Mil. Total Assets at the begining of this year (Sep23) was $349.0 Mil. Long-Term Debt & Capital Lease Obligation was $110.2 Mil. Total Current Assets was $318.2 Mil. Total Current Liabilities was $44.9 Mil. |
Net Income was -12.232 + -6.789 + -6.371 + 2.565 = $-22.8 Mil. Revenue was 49.982 + 56.914 + 60.123 + 67.275 = $234.3 Mil. Gross Profit was 14.177 + 16.513 + 16.69 + 24.653 = $72.0 Mil. Average Total Assets from the begining of last year (Sep22) to the end of last year (Sep23) was (300.558 + 348.461 + 340.788 + 343.027 + 348.997) / 5 = $336.3662 Mil. Total Assets at the begining of last year (Sep22) was $300.6 Mil. Long-Term Debt & Capital Lease Obligation was $152.0 Mil. Total Current Assets was $273.7 Mil. Total Current Liabilities was $41.8 Mil. |
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
ADMA Biologics's current Net Income (TTM) was 68.1.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
ADMA Biologics's current Cash Flow from Operations (TTM) was 86.1.
==> Positive ==> Score 1.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Score 1 if it's higher, 0 if it's lower.
ROA (This Year) | = | Net Income | / | Total Assets (Sep23) |
= | 68.132 | / | 348.997 | |
= | 0.19522231 |
ROA (Last Year) | = | Net Income | / | Total Assets (Sep22) |
= | -22.827 | / | 300.558 | |
= | -0.07594874 |
ADMA Biologics's return on assets of this year was 0.19522231. ADMA Biologics's return on assets of last year was -0.07594874.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Score 1 if CFROA > ROA, 0 if CFROA <= ROA.
ADMA Biologics's current Net Income (TTM) was 68.1. ADMA Biologics's current Cash Flow from Operations (TTM) was 86.1.
==> 86.1 > 68.1 ==> CFROA > ROA ==> Score 1.
Funding
Question 5. Change in Gearing or Leverage
Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.
Score 0 if this year's gearing is higher, 1 otherwise.
Gearing (This Year: Sep24) | = | Long-Term Debt & Capital Lease Obligation | / | Average Total Assets from Sep23 to Sep24 |
= | 110.191 | / | 359.2142 | |
= | 0.30675569 |
Gearing (Last Year: Sep23) | = | Long-Term Debt & Capital Lease Obligation | / | Average Total Assets from Sep22 to Sep23 |
= | 151.991 | / | 336.3662 | |
= | 0.45186169 |
ADMA Biologics's gearing of this year was 0.30675569. ADMA Biologics's gearing of last year was 0.45186169.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Current Ratio (This Year: Sep24) | = | Total Current Assets | / | Total Current Liabilities |
= | 318.193 | / | 44.891 | |
= | 7.08812457 |
Current Ratio (Last Year: Sep23) | = | Total Current Assets | / | Total Current Liabilities |
= | 273.699 | / | 41.841 | |
= | 6.54140675 |
ADMA Biologics's current ratio of this year was 7.08812457. ADMA Biologics's current ratio of last year was 6.54140675.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
ADMA Biologics's number of shares in issue this year was 244.804. ADMA Biologics's number of shares in issue last year was 233.761.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Gross Margin (This Year: TTM) | = | Gross Profit | / | Revenue |
= | 187.306 | / | 382.809 | |
= | 0.48929362 |
Gross Margin (Last Year: TTM) | = | Gross Profit | / | Revenue |
= | 72.033 | / | 234.294 | |
= | 0.30744705 |
ADMA Biologics's gross margin of this year was 0.48929362. ADMA Biologics's gross margin of last year was 0.30744705.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Asset Turnover (This Year) | = | Revenue | / | Total Assets at the Beginning of This Year (Sep23) |
= | 382.809 | / | 348.997 | |
= | 1.09688335 |
Asset Turnover (Last Year) | = | Revenue | / | Total Assets at the Beginning of Last Year (Sep22) |
= | 234.294 | / | 300.558 | |
= | 0.77953007 |
ADMA Biologics's asset turnover of this year was 1.09688335. ADMA Biologics's asset turnover of last year was 0.77953007.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score | = | Que. 1 | + | Que. 2 | + | Que. 3 | + | Que. 4 | + | Que. 5 | + | Que. 6 | + | Que. 7 | + | Que. 8 | + | Que. 9 |
= | 1 | + | 1 | + | 1 | + | 1 | + | 1 | + | 1 | + | 0 | + | 1 | + | 1 | |
= | 8 |
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
ADMA Biologics has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.
ADMA Biologics (NAS:ADMA) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Thank you for viewing the detailed overview of ADMA Biologics's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.
Adam S Grossman | director, officer: President and CEO | 65 COMMERCE WAY, HACKENSACK NJ 07601 |
Lawrence P. Guiheen | director | 65 COMMERCE WAY, HACKENSACK NJ 07601 |
Jerrold B Grossman | director | 65 COMMERCE WAY, HACKENSACK NJ 07601 |
Young Kwon | director | C/O MOMENTA PHARMACEUTICALS INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142 |
Steve Elms | director | 888 SEVENTH AVE, 29TH FL, NEW YORK NY 10106 |
Alison Cecily Finger | director | C/O BLUEBIRD BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142 |
Bryant Fong | director | 2170 VALLEJO STREET #101, SAN FRANCISCO CA 94123 |
Brian Lenz | officer: EVP, CFO | 65 COMMERCE WAY, HACKENSACK NJ 07601 |
Martha J Demski | director | 7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122 |
Perceptive Life Sciences Master Fund Ltd | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
James Mond | officer: CSO/CMO | 65 COMMERCE WAY, HACKENSACK NJ 07601 |
Biotest Divestiture Trust | 10 percent owner | C/O ERIC ROSENBACH, TRUSTEE, 402 NORFOLK STREET, CAMBRIDGE MA 02139 |
Perceptive Advisors Llc | 10 percent owner | 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Joseph Edelman | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Eric I Richman | director | C/O REV CAPITAL II, LLC, 9740 SORREL AVE, POTOMAC MD 20854 |
From GuruFocus
By GuruFocus News • 11-05-2024
By GuruFocus News • 12-20-2024
By Marketwired • 10-31-2024
By Marketwired • 10-29-2024
By Marketwired • 11-02-2024
By Marketwired • 01-07-2025
By Marketwired • 10-29-2024
By Marketwired • 11-04-2024
By PRNewswire • 11-19-2024
By Marketwired • 11-07-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.